Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ulimorelin - Lyric Pharmaceuticals

Drug Profile

Ulimorelin - Lyric Pharmaceuticals

Alternative Names: LP 101; TZP-101; Ulimorelin hydrochloride

Latest Information Update: 14 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tranzyme
  • Developer Lyric Pharmaceuticals; Norgine; Tranzyme Pharma
  • Class Macrocyclic compounds; Small molecules
  • Mechanism of Action Ghrelin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Nutrition disorders
  • Discontinued Cachexia; Digestive system disorders; Gastroparesis; Postoperative ileus

Most Recent Events

  • 05 Mar 2018 Lyric Pharmaceuticals completes enrolment in the phase II PROMOTE trial for Nutrition disorders in USA, Canada, Spain and Netherlands (IV)
  • 01 Mar 2018 Lyric Pharmaceuticals completes the phase II PROMOTE trial in Nutritional disorders (In patients with enteral feeding tolerance) in USA, Netherlands, Canada and Spain (NCT02784392)
  • 23 Jan 2018 Adverse events data from the phase II trial in Nutritional disorders released by Lyric Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top